This article is more than 5 years old. Information may no longer be current.
LEO Pharma, Antares Pharma to market Otrexup for psoriasis
Click Here to Manage Email Alerts
Antares Pharma announced it will pair with LEO Pharma to market its single-dose, disposable auto-injector containing methotrexate to dermatologists for treating adults with severe recalcitrant psoriasis.
The FDA recently approved Otrexup, a subcutaneous methotrexate for weekly self-administration, for adults with severe rheumatoid arthritis who have experienced insufficient response or were unable to tolerate first-line therapy such as nonsteroidal anti-inflammatory drugs. The drug also is indicated for adults with severe recalcitrant psoriasis and children with active polyarticular juvenile idiopathic arthritis.
Under the agreement, LEO Pharma will be responsible for promotion and marketing activities in dermatology, according to a news release. Antares may receive up to $20 million in milestone payments, including $5 million upfront, under the agreement and will pay LEO Pharma a percentage of Otrexup net sales generated in dermatology.
“We are very pleased to be working with LEO Pharma on the launch of Otrexup,” PaulWotton, PhD, president and CEO of Antares Pharma, said in a press release. “With a dedicated US sales force … focused solely on the treatment of psoriasis, we believe LEO Pharma will be able to introduce and establish Otrexup as an important new treatment option with significant growth potential in dermatology while complementing our own dedicated sales representatives detailing Otrexup for rheumatoid arthritis.”
“We are excited to launch and promote Otrexup to dermatologists as an important new treatment option for psoriasis patients,” Lars Olsen, executive vice president of LEO Pharma A/S, said in the release.